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Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the
Treatment of Hemiparesis in Adults With Upper Limb Spasticity
Previously Treated With Botulinum Toxin: Subanalysis From a
Phase 3 Randomized Controlled Trial
Christina Marciniak, MD, Peter McAllister, MD, Heather Walker, MD,
Allison Brashear, MD, Steven Edgley, MD, Thierry Deltombe, MD,
Svetlana Khatkova, MD, Marta Banach, MD, Fatma Gul, MD, MMM, Claire Vilain, MD,
Philippe Picaut, MD, Anne-Sophie Grandoulier, MSc, Jean-Michel Gracies, MD, PhD, for
the International AbobotulinumtoxinA Adult Upper Limb Spasticity Study GroupAbstractObjective: To assess the efficacy and safety of abobotulinumtoxinA in adults with upper limb spasticity previously treated with
botulinum toxin A (BoNT-A).
Design: A post hoc analysis from a Phase 3, prospective, double-blind, randomized, placebo-controlled study (NCT01313299).
Setting: A total of 34 neurology or rehabilitation clinics in 9 countries.
Participants: Adults aged 18-80 years with hemiparesis, 6 months after stroke or traumatic brain injury. This analysis focused on
a subgroup of subjects with previous onabotulinumtoxinA or incobotulinumtoxinA treatment (n ¼ 105 of 243 in the total trial
population) in the affected limb. The mean age was 52 years, and 62% were male.
Intervention: Study subjects were randomized 1:1:1 to receive a single injection session with abobotulinumtoxinA 500 or 1000 U
or with placebo in the most hypertonic muscle group among the elbow, wrist, or finger flexors (primary target muscle group
[PTMG]), and 2 additional muscle groups from the upper limb.
Main Outcome Measurements: Efficacy and safety measures were assessed, including muscle tone (Modified Ashworth Scale
[MAS] in the PTMG), Physician Global Assessment (PGA), perceived function, spasticity, active movement, and treatment-
emergent adverse events.
Results: At week 4, more subjects had 1 grade improvement in MAS for the PTMG with abobotulinumtoxinA versus placebo
(abobotulinumtoxinA 500 U, 81.1%; abobotulinumtoxinA 1000 U, 75.0%; placebo, 25.0%). PGA scores 1 were achieved by 75.7%
and 87.5% of abobotulinumtoxinA 500 and 1000 U subjects versus 41.7% with placebo. Perceived function (Disability Assessment
Scale), spasticity angle (Tardieu Scale), and active movement were also improved with abobotulinumtoxinA. There were no
treatment-related deaths or serious adverse events.
Conclusions: The efficacy and safety of abobotulinumtoxinA in subjects previously treated with BoNT-A were consistent with
those in the total trial population. Hence, abobotulinumtoxinA is a treatment option in these patients, and no difference in initial
dosing appears to be required compared to that in individuals not treated previously.
Level of Evidence: IIIIntroduction
Upper limb spasticity (ULS) is common after stroke or
traumatic brain injury (TBI). The impact can be highly
significant, including abnormal hand and arm posi-
tions, impaired self-care, and limited passive/active1934-1482 ª 2017 by the American Academy of Physical Medicine and Reha
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
http://dx.doi.org/10.1016/j.pmrj.2017.06.007range of motion, as well as additional burden to the
caregiver [1-5].
The effectiveness of treatment with intramuscularly
injected botulinum toxin A (BoNT-A) in reducing muscle
tone in patients with ULS is well established [5-8].
Several guidelines now recommend BoNT-A injectionsbilitation. This is an open access article under the CC BY-NC-ND license
1182 AbobotulinumtoxinA for Hemiparesis in Upper Limb Spasticityas a first-line treatment option in these patients
[6,7,9-11].
AbobotulinumtoxinA (Dysport; Ipsen Biopharm,
Wrexham, UK) is a BoNT-A preparation approved in the
United States and Europe for the treatment of ULS in
adult patients [12,13]. A recent clinical trial examined
the efficacy and safety of a single injection session of
abobotulinumtoxinA (500 or 1000 U) in 243 adults with
ULS who had hemiparesis at least 6 months after stroke
or TBI [14]. The effects observed included improve-
ments in muscle tone, perceived function, spasticity,
and active range of motion. Furthermore, the treatment
was well tolerated, and all treatment-related adverse
events (AEs) were mild or moderate in severity.
Among the subjects enrolled in this study, 105 had
previously undergone treatment in the upper limb with
onabotulinumtoxinA or incobotulinumtoxinA. The aim of
the present analysis was to assess the efficacy and
safety of abobotulinumtoxinA in adults with ULS who
had been previously treated with a BoNT-A, and to
describe the doses of abobotulinumtoxinA administered
to these subjects.
MethodsStudy Design and SubjectsThis was a post hoc analysis of data from a phase 3,
prospective, double-blind, randomized, placebo-
controlled study conducted in 34 neurology or rehabili-
tation clinics in 9 countries: Belgium, Czech Republic,
France, Hungary, Italy, Poland, Russia, Slovakia, and the
United States. The study is registered with ClinicalTrials.
gov (NCT01313299).
The trial was performed between August 4, 2011, and
September 4, 2013, in compliancewith the Declaration of
Helsinki, Good Clinical Practice guidelines, and local
regulatory requirements, and with the approval of rele-
vant institutional review boards and ethics committees.Figure 1. Patient population. AboBoNT-A ¼ abobAll subjects signed written informed consent forms
before trial entry.
Full details of the study design have been reported
previously [14]. A summary is given below.
All subjects were between 18 and 80 years of age and
had hemiparesis for at least 6 months after a clinically
defined stroke episode (World Health Organization
criteria) or one episode of TBI, occurring 6 months
before enrollment. Included subjects were also required
to have the following: a Modified Ashworth Scale (MAS)
[15] score 3 in the primary target muscle group (PTMG;
the muscle group with the highest MAS score among the
elbow, wrist, and finger flexors); a Disability Assessment
Scale (DAS) [16,17] score 2 rated on a 4-point scale
from 0 (no disability) to 3 (severe disability) in the
domains of dressing, hygiene, limb position, or pain; a
spasticity angle 10 in the PTMG [18,19]; and a mean
Modified Frenchay Scale (MFS) score of 1-8 out of a total
possible score of 10 [18].
Key exclusion criteria included major limitations in
the passive range of motion in the paretic limb
(maximum passive elbow extension <150 or maximum
passive wrist finger extension <70), physical therapy
initiated <4 weeks before the expected enrollment,
treatment with BoNT-A of any type in the previous
4 months, and previous surgery or administration of
alcohol or phenol in the study limb. A full list of exclu-
sion criteria has been published previously [14].
A total of 243 study subjects were enrolled and ran-
domized 1:1:1 to receive a single injection session with
abobotulinumtoxinA 500 U, abobotulinumtoxinA 1000 U,
or placebo in selected overactive upper limb muscles
(Figure 1). Computer-generated randomization lists
were independently created, and treatment numbers
were assigned via a 24-hour interactive voice response
system from an external contract research organization
(S-Clinica, Brussels, Belgium). A double-dummy tech-
nique was used to maintain the masking of patients and
investigators.otulinumtoxinA; BoNT-A ¼ botulinum toxin A.
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they had been previously treated with a BoNT-A. The
present analysis comprises only the 105 subjects who
had been previously treated in the affected limb with a
BoNT-A other than abobotulinumtoxinA: 36 subjects
from the placebo group, 37 from the abobotulinumtoxinA
500-U group, and 32 from the abobotulinumtoxinA
1000-U group (Figure 1).ProceduresStudy drugs (abobotulinumtoxinA or placebo) were
reconstituted with saline solution to a volume of 5 mL.
This volume was injected into the PTMG (selected from
among the elbow, wrist, and finger flexors) and at least
2 other upper limb muscles (from among the elbow,
wrist or finger flexors, or shoulder extensors) in a single
injection session. Electrical stimulation was the only
technique allowed for targeting the muscle [20].
Mandatory volumes for the PTMG were 2-3 mL for
elbow flexors (2 mL for brachialis and an extra 1 mL for
brachioradialis if injected), 2 mL for wrist flexors (1 mL
for each of the flexor carpi radialis and flexor carpi
ulnaris), and 2 mL for extrinsic finger flexors (1 mL each
for flexor digitorum profundus and flexor digitorum
superficialis). The remainder of the 5 mL was injected
into other upper limb muscles, as selected by the
investigator.
Mandatory assessment visits were made at weeks 1,
4, and 12.Outcome MeasuresMultiple efficacy endpoints are included within the
present analysis. Muscle tone was assessed in the PTMG
using the MAS, which measures resistance during passive
soft-tissue stretching on a scale of 0 (no increase in
muscle tone) to 4 (affected part rigid in flexion or
extension). This endpoint was assessed as the propor-
tion of responders (subjects with a 1 grade improve-
ment) in each group. Treatment response was evaluated
according to the Physician Global Assessment (PGA), a
9-point scale from e4 (markedly worse) to 4 (markedly
improved), measured as the percentage of responders
(subjects with a score 1) in each group. Perceived
upper limb function was assessed by a DAS, recorded as
the percentage of responders (subjects with a 1 grade
improvement) in each group. The principal target of
treatment was selected by the patient and physician
from 1 of the 4 domains with a score 2 at baseline.
Spasticity was also evaluated, based on the Tardieu
Scale, measuring angle of arrest at slow speed (XV1),
angle of catch at fast speed (XV3) and spasticity angle
(X; defined as XV1eXV3) in extrinsic finger, elbow, and
wrist flexor muscles.
Other assessments included active range of motion
(AROM) for joint extension, against extrinsic finger,elbow and wrist flexor muscles; active upper limb
function assessed using the Modified Frenchay Scale
(which assesses 10 activities of daily living on a scale of
0 [no movement] to 10 [normal movement]); and ease of
applying a splint, if applicable, measured using a 6-point
scale from 0 (no splint needed) to 5 (splint needed but
unable to apply).
Safety assessments included AEs, classified as mild,
moderate, severe, or serious.Statistical AnalysisThis was a post hoc analysis, and the study was not
powered to detect statistical significance. Hence, only
descriptive statistics (mean, standard error of the
mean, standard deviation, and range) are provided.
Missing data were not imputed.
ResultsBaseline CharacteristicsThe baseline characteristics of subjects included in
this analysis were well matched between groups
(Table 1). The mean age was 52 years, and 62% of all
subjects were male. The mean time since stroke or TBI
was 5-10 years. In total, 93 subjects (88.6%) had
received previous treatment with onabotulinumtoxinA
(mean dose 293 U); 14 subjects (13.3%) had been pre-
viously treated with incobotulinumtoxinA (mean dose
312 U). The PTMG was the extrinsic finger flexors for 55
subjects (52.4%), the elbow flexors for 31 (29.5%), and
wrist flexors for 19 (18.1%).Doses AdministeredThe doses of abobotulinumtoxinA administered to
each muscle are provided in Table 2. For the finger
flexors, abobotulinumtoxinA was administered to the
flexor digitorum profundus in 71.0% of subjects, either
as PTMG or non-PTMG. Mean doses were 100.0 U (PTMG)
and 62.5 U (non-PTMG) in the 500-U group, and 194.4 U
(PTMG) and 181.3 U (non-PTMG) in the 1000-U group.
AbobotulinumtoxinA was injected into the flexor dig-
itorum superficialis in 84.1% of subjects, with mean
doses of 100.0 U (PTMG) and 82.5 U (non-PTMG) in the
500-U group, and 200.0 U (PTMG) and 196.2 U (non-
PTMG) in the 1000-U group.
For the wrist flexors, abobotulinumtoxinA was
administered to the flexor carpi radialis in 84.1% of
subjects. Mean doses were 100.0 U (PTMG) and 90.6 U
(non-PTMG) in the 500-U group, and 191.7 U (PTMG) and
174.7 U (non-PTMG) in the 1000-U group. Furthermore,
abobotulinumtoxinA was administered to the flexor
carpi ulnaris in 68.1% of subjects, with the mean dose
ranging from 94.1 to 191.7 U.
Table 1
Baseline characteristics of study participants
Parameter Placebo (n ¼ 36) AboBoNT-A 500 U (n ¼ 37) AboBoNT-A 1000 U (n ¼ 32)
Age, y, mean (SD) 49.6 (22-69) 53.8 (22-75) 50.9 (23-76)
Gender ratio, male/female, % 58.3/41.7 59.5/40.5 68.8/31.3
Affected arm, n (%)
Left 17 (47.2) 17 (45.9) 22 (68.8)
Right 19 (52.8) 20 (54.1) 10 (31.3)
Cause of spasticity, n (%)
Stroke 29 (80.6) 32 (86.5) 30 (93.8)
TBI 7 (19.4) 5 (13.5) 2 (6.3)
Time since event, y, mean (SD, range)
Stroke 6.0 (4.8, 1.7-20.9) 7.6 (4.5, 1.0-16.8) 4.6 (2.6, 0.7-11.3)
TBI 4.6 (2.6, 0.8-7.4) 9.7 (5.8, 4.9-18.3) 8.7 (2.8, 6.8-10.7)
Previous BoNT-A treatment, n (%)*
OnabotulinumtoxinA 32 (88.9) 35 (94.6) 26 (81.3)
IncobotulinumtoxinA 6 (16.7) 4 (10.8) 4 (12.5)
Other† 3 (8.3) 1 (2.7) 4 (12.5)
Dose of previous treatment, U, mean (range)
OnabotulinumtoxinA 287.3 (50-600) 291.7 (50-650) 302.8 (70-800)
IncobotulinumtoxinA 291.3 (170-425) 425.0 (200-1000) 180.0 (100-200)
Other† 966.7 (200-2500) e 4500.0 (4500-4500)
Primary target muscle group, n (%)
Elbow flexors 11 (30.6) 12 (32.4) 8 (25.0)
Extrinsic finger flexors 18 (50.0) 19 (51.4) 18 (56.3)
Wrist flexors 7 (19.4) 6 (16.2) 6 (18.8)
Principal target of treatment, n (%)
Dressing 10 (27.8) 7 (18.9) 7 (21.9)
Hygiene 5 (13.9) 12 (32.4) 5 (15.6)
Limb position 16 (44.4) 17 (45.9) 18 (56.3)
Pain 5 (13.9) 1 (2.7) 2 (6.3)
AboBoNT-A ¼ abobotulinumtoxinA; BoNT-A ¼ botulinum toxin A; SD ¼ standard deviation; TBI ¼ traumatic brain injury; y ¼ years.
* Some subjects had previously received more than one other BoNT-A.
† Included Lantox, Myobloc, and treatments for which the drug name was unknown.
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administered into the brachialis in 63.8% of subjects,
with mean dose ranging from 124.0 to 400.0 U, and into
the brachioradialis in 34.8% of subjects, with mean dose
ranging from 81.3 to 200.0 U. The biceps brachii could
not be selected as a PTMG, but abobotulinumtoxinA was
administered into this muscle in 31.9% of subjects, with
a mean dose of 103.3 U in the 500-U group and 228.6 U in
the 1000-U group.
Finally, although the shoulder muscles could not be
selected as a PTMG, the protocol allowed abobotuli-
numtoxinA administration in these muscles, and 10.1%
of subjects were injected in shoulder muscles (Table 2).Disposition of SubjectsAll randomized subjects included in this analysis had
efficacy data available at week 4, the main time point of
the study. At week 12, data were not available for 5
subjects: 3 who withdrew between weeks 4 and 12 (2 in
the placebo group [1 for an adverse event and 1 for a
protocol deviation] and 1 in the abobotulinumtoxinA 500
U group [for an adverse event]) and 2 subjects who had
missing data at week 12 (both in the abobotulinumtoxinA
500 U group).EfficacyWith regard to muscle tone, there were more
responders (subjects with 1 grade improvement in MAS
score for the PTMG) in the 2 abobotulinumtoxinA groups
compared with placebo at weeks 1, 4, and 12 (Figure 2).
The number of responders peaked at week 4: 81.1 and
75.0% in the abobotulinumtoxinA 500-U and 1000-U
groups versus 25.0% in the placebo group.
Physician-perceived clinical improvement rates were
also higher with abobotulinumtoxinA. At week 4,
PGA score 1 had been achieved by 75.7% and 87.5%
of subjects treated with abobotulinumtoxinA 500 and
1000 U, respectively, compared with 41.7% of the
placebo group (Figure 3). At 12 weeks, differences in
clinical improvement rates were still evident between
groups (45.9%, 53.1%, and 33.3% of abobotulinumtoxinA
500-U, 1000-U, and placebo subjects, respectively).
Perceived function was assessed by a DAS at weeks 4
and 12. At week 4, the proportion of subjects with a 1
grade decrease from baseline in DAS score for the
principal target of treatment was greater with abobo-
tulinumtoxinA 500 or 1000 U (62.2% and 53.1%, respec-
tively) compared with placebo (44.4%) (Figure 4).
Differences in response rates between groups were
still present at week 12 (45.9%, 56.3%, and 38.9% of
Table 2
Prevalence and doses of abobotulinumtoxinA administered to each muscle group
Muscle Group
AboBoNT-A
500 U (n ¼ 37)
n








n ¼ 69), n (%)
Finger muscles
Flexor digitorum profundus 49 (71.0)
PTMG 19 18 37 (53.6)
100.0 (0, 100-100) 194.4 (23.6, 100-200)
Non-PTMG 4 8 12 (17.4)
62.5 (25.0, 50-100) 181.3 (37.2, 100-200)
Flexor digitorum superficialis 58 (84.1)
PTMG 19 18 37 (53.6)
100.0 (0, 100-100) 200.0 (0, 200-200)
Non-PTMG 8 13 21 (30.4)
82.5 (24.3, 50-100) 196.2 (43.1, 100-300)
Flexor pollicis longus 10 13 23 (33.3)
72.5 (27.5, 25-100) 150 (45.6, 100-200)
Adductor pollicis 3 6 9 (13.0)
25.0 (0, 25-25) 50.0 (0, 50-50)
Wrist muscles
Flexor carpi radialis 55 (79.7)
PTMG 6 6 12 (17.4)
100.0 (0, 100-100) 191.7 (20.4, 150-200)
Non-PTMG 24 19 43 (62.3)
90.6 (19.2, 50-100) 174.7 (54.9, 100-300)
Flexor carpi ulnaris 47 (68.1)
PTMG 6 6 12 (17.4)
100.0 (0, 100-100) 191.7 (20.4, 150-200)
Non-PTMG 16 19 35 (50.7)
94.1 (30.5, 50-180) 156.8 (52.2, 80-200)
Elbow muscles
Brachioradialis 24 (34.8)
PTMG 8 4 12 (17.4)
100.0 (0, 100-100) 200.0 (0, 200-200)
Non-PTMG 8 4 12 (17.4)
81.3 (25.9, 50-100) 105.0 (42.0, 50-150)
Brachialis 44 (63.8)
PTMG 12 8 20 (29.0)
187.5 (43.3, 50-200) 400.0 (0, 400-400)
Non-PTMG 15 9 24 (34.8)
124.0 (52.9, 50-200) 211.1 (78.8, 100-400)
Biceps brachii 15 7 22 (31.9)
103.3 (29.7, 50-200) 228.6 (75.6, 200-400)
Pronator teres 6 9 15 (21.7)
66.7 (25.8, 50-100) 136.7 (51.0, 80-200)
Shoulder muscles
Triceps brachii (long head) 0 0 0
Pectoralis major 2 2 4 (5.8)
100.0 (0, 100-100) 250.0 (70.7, 200-300)
Subscapularis 1 0 1 (1.4)
100.0 (e, 100-100)
Latissimus dorsi 1 1 2 (2.9)
100.0 (e, 100-100) 100.0 (e, 100-100)
AboBoNT-A ¼ abobotulinumtoxinA; PTMG ¼ primary target muscle group; SD ¼ standard deviation.
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jects, respectively).
Spasticity was evaluated at weeks 1, 4, and 12. The
angle of catch (XV3) in the finger, elbow, and wrist
flexors improved from baseline to week 4 by a
mean of 46.3, 18.0, and 27.5, respectively, across
abobotulinumtoxinA-treated subjects (Table 3), whereasthe mean improvements in placebo-treated subjects
were 10.7, 4.6, and e1.5, respectively. Furthermore,
the overall spasticity angle (X) in the finger, elbow and
wrist flexors improved from baseline to week 4 by a
mean of e31.3, e15.9, and, e14.6, respectively, in
abobotulinumtoxinA-treated subjects, compared with
e11.0, e4.7, and 3.3 in the placebo group.
Figure 2. Responders to abobotulinumtoxinA according to MAS score improvement for the PTMG. Responders were defined as those subjects with a
1 grade improvement on the MAS for the PTMG. AboBoNT-A ¼ abobotulinumtoxinA; MAS ¼ Modified Ashworth Scale; PTMG ¼ primary target
muscle group.
1186 AbobotulinumtoxinA for Hemiparesis in Upper Limb SpasticityActive movement was also assessed at the same time
points as spasticity. For the finger, elbow, and wrist
flexors, AROM increased from baseline to week 4 by a
mean of 19.0, 11.9, and 14.6, respectively, in sub-
jects treated with abobotulinumtoxinA, compared with
e1.3, 4.2, and 0 in the placebo group.
The evolution of both the spasticity and AROM data be-
tween weeks 1 and 12 are presented in Supplementary
Table 1.
A small increase in MFS score from baseline was
observed at week 4 in each of the 3 groups, with a
numerically greater increase in the abobotulinumtoxinA
500-U dose group: 0.29 (standard deviation [SD] ¼ 0.43)
versus 0.15 (SD ¼ 0.43) and 0.10 (SD ¼ 0.36) with pla-
cebo and abobotulinumtoxinA 1000 U, respectively.
Finally, ease of applying a splint atweek 4was improved
in the abobotulinumtoxinA 500-U and 1000-U groups,
whereas there was nomarked change in the placebo group
(change from baseline:e0.4,e0.4, and 0.1, respectively).SafetyFigure 3. Clinical improvement with abobotulinumtoxinA according to
PGA score 1. AboBoNT-A ¼ abobotulinumtoxinA; PGA ¼ Physician
Global Assessment.Treatment-emergent AEs were experienced by 48.6%,
40.6%, and 22.2% of subjects in the abobotulinumtoxinA
500-U and 1000-U and placebo groups, respectively
(Table 4). The most common treatment-emergent AE
among abobotulinumtoxinA-treated subjects was naso-
pharyngitis (n ¼ 5; 7.2%). No deaths or serious AEs were
assessed by the investigator as related to treatment.
Discussion
This analysis of data from a phase 3 clinical study
assessed the effect of abobotulinumtoxinA on various
efficacy and safety parameters in hemiparetic adults
who had previously undergone BoNT-A treatmentfor ULS. Improvements were observed in muscle tone,
spasticity angle, active movement, perceived function,
and overall clinical improvement after treatment with
abobotulinumtoxinA 500 or 1000 U. Importantly, all of
these patients were treated at least 4 months after
their last injection with either onabotulinumtoxinA or
incobotulinumtoxinA. Hence, the results demonstrate
that individuals treated with abobotulinumtoxinA
4 months after prior treatment with another BoNT-A
experience a similar benefit and side effect profile.
The magnitude of the improvements observed in the
present analysis was similar to that observed for the
total population of the trial, which included both sub-
jects who had been previously treated with a BoNT-A
and those who had not [14]. For example, the number
of responders with regard to MAS score at 4 weeks was
81.1% and 75.0% in the abobotulinumtoxinA 500-U and
1000-U groups in the present analysis, compared to
Figure 4. Subjects with 1 grade decrease in DAS score for the prin-
cipal target of treatment. AboBoNT-A ¼ abobotulinumtoxinA; DAS ¼
Disability Assessment Scale.
1187C. Marciniak et al. / PM R 9 (2017) 1181-119073.8% and 78.5%, respectively, in the total study popu-
lation. Similarly, the number of responders with regard
to the DAS at 4 weeks was 62.2% and 53.1%, respec-
tively, in the present analysis, compared to 50.0% and
62.0% in the total trial population.
As expected after a single injection, there were no
significant differences with abobotulinumtoxinA versus
placebo using the MFS in this population. There was a
similar finding in the total trial population [14].
The safety profile of abobotulinumtoxinA in this
analysis was consistent with the total trial populationTable 3






) Placebo e0.3 (4.8)
AboBoNT-A
500 U 10.2 (5.6)
1000 U 19.7 (7.0)
Either dose 15.0 (4.5)
XV3 (
) Placebo 10.7 (7.4)
AboBoNT-A
500 U 46.0 (8.8)
1000 U 46.6 (7.3)
Either dose 46.3 (5.6)
X () Placebo e11.0 (8.4)
AboBoNT-A
500 U e35.9 (7.4)
1000 U e26.9 (8.1)
Either dose e31.3 (5.5)
Active range of motion
AROM () Placebo e1.3 (6.5)
AboBoNT-A
500 U 25.2 (5.5)
1000 U 12.8 (5.9)
Either dose 19.0 (4.1)
AboBoNT-A ¼ abobotulinumtoxinA; AROM ¼ active range of motion; SEM ¼
of arrest at slow speed; XV3 ¼ angle of catch at fast speed.and with its known profile across multiple studies con-
ducted in patients with spasticity [14,21].
Hence, overall, the efficacy and safety of abobotuli-
numtoxinA in patients previously treated with BoNT-A
were similar to those in the total trial population.
In the total trial population, there was some evidence
that the 1000-U dose might provide additional clinical
benefit compared with the 500-U dose [14]. There was
no clear indication of such an effect in the current
analysis, however, which may be explained by the fact
that the study was not powered to detect such
differences.Study Strengths and LimitationsThekey strength of the present analysis is that thedata
were derived from a Phase 3, prospective, randomized,
placebo-controlled study. In addition, the degree of
confidence that the efficacy of abobotulinumtoxinA is
indeed as high in previously BoNT-A-treated patients as in
the total trial population is increasedby thewide range of
efficacy endpoints assessed (and the similarity of thedata
in the 2 populations).
A key limitation is the lack of detailed efficacy and
safety data relating to previous injection(s) with inco-
botulinumtoxinA or onabotulinumtoxinA, which makes
direct comparison between different types of BoNT-A
impossible. In addition, the study was not powered for
this analysis, and hence only descriptive statistics could




e0.1 (0.9) 1.8 (4.5)
2.9 (0.9) 13.6 (3.2)
0.8 (1.4) 12.0 (3.5)
2.1 (0.8) 12.9 (2.3)
4.6 (2.7) e1.5 (4.3)
19.2 (4.6) 25.5 (5.8)
15.9 (3.9) 30.0 (4.6)
18.0 (3.2) 27.5 (3.8)
e4.7 (2.7) 3.3 (3.4)
e16.4 (4.6) e11.9 (6.6)
e15.1 (3.9) e18.0 (5.0)
e15.9 (3.2) e14.6 (4.4)
4.2 (2.7) 0.0 (4.9)
6.8 (3.8) 16.6 (5.5)
18.1 (4.7) 12.4 (4.2)
11.9 (3.0) 14.6 (3.5)
standard error of the mean; X ¼ spasticity angle (XV1eXV3); XV1 ¼ angle
Table 4
Adverse events (AEs) after injection




500 U (n ¼ 37)
AboBoNT-A 1000 U
(n ¼ 32)
Any treatment-emergent AEs 8 (22.2) 18 (48.6) 13 (40.6)
Infections
Nasopharyngitis 1 (2.8) 4 (10.8) 1 (3.1)
Sinusitis 0 (0) 1 (2.7) 1 (3.1)
Bronchitis 0 (0) 1 (2.7) 1 (3.1)
Urinary tract infection 0 (0) 1 (2.7) 1 (3.1)
Investigations
Increased g-glutamyl transferase 0 (0) 1 (2.7) 0 (0)
Increased triglycerides 0 (0) 2 (5.4) 0 (0)
Increased blood glucose 0 (0) 2 (5.4) 0 (0)
Musculoskeletal and connective tissue disorders
Muscular weakness 2 (5.6) 1 (2.7) 1 (3.1)
Back pain 0 (0) 0 (0) 2 (6.3)
Arthralgia 1 (2.8) 0 (0) 0 (0)
Musculoskeletal pain 1 (2.8) 1 (2.7) 1 (3.1)
Nervous system disorders
Headache 0 (0) 1 (2.7) 1 (3.1)
General disorders and injection site conditions
Injection site erythema 0 (0) 0 (0) 2 (6.3)
Injection site bruising 1 (2.8) 0 (0) 1 (3.1)
Asthenia 0 (0) 1 (2.7) 0 (0)
Injection site pain 2 (5.6) 1 (2.7) 0 (0)
Respiratory, thoracic, and mediastinal disorders
Cough 0 (0) 0 (0) 1 (3.1)
Epistaxis 0 (0) 1 (2.7) 0 (0)
Gastrointestinal disorders
Diarrhea 0 (0) 0 (0) 1 (3.1)
Skin and subcutaneous tissue disorders
Pruritus 1 (2.8) 0 (0) 1 (3.1)
Serious AEs* 1 (2.8) 2 (5.4) 1 (3.1)
Behçet syndrome 0 (0) 1 (2.7) 0 (0)
Cardiovascular disorder 0 (0) 1 (2.7) 0 (0)
Deep vein thrombosis 1 (2.8) 0 (0) 0 (0)
Muscular weakness 1 (2.8) 0 (0) 0 (0)
Sepsis 0 (0) 1 (2.7) 0 (0)
Syncope 0 (0) 0 (0) 1 (3.1)
AboBoNT-A ¼ abobotulinumtoxinA.
* If a participant experienced more than one event, that individual was counted only once.
1188 AbobotulinumtoxinA for Hemiparesis in Upper Limb Spasticityfor subanalysis of subjects who were previously treated
and untreated with a BoNT-A, a comparison was made
only against the total trial population and not against
previously untreated subjects.
Conclusions
AbobotulinumtoxinA 500 U and 1000 U were each
associated with improvements in muscle tone,
perceived function, spasticity angle, and active move-
ment in subjects with hemiparesis and ULS who had
been previously treated with a BoNT-A. Efficacy and
safety in this subgroup of subjects were comparable
with those in the total trial population, at similar doses
of abobotulinumtoxinA.
Based on these results, abobotulinumtoxinA appears
to be a treatment option in hemiparetic patients pre-
viously treated with onabotulinumtoxinA or incobotuli-
numtoxinA for ULS. The data do not suggest that anydifference in initial dosing with abobotulinumtoxinA is
required when initiating treatment in patients who have
been previously treated with BoNT-A versus previously
untreated patients.
Acknowledgments
The authors thank Dr Timothy Ryder from Water-
meadow Medical, funded by Ipsen, for editorial assis-
tance in developing the manuscript.
The members of the International Abobotulinumtox-
inA Adult Upper Limb Spasticity Study Group are as
follows:
Z. Ayyoub (USA), M. Banach (Poland), D. Bensmail
(France), A.R. Bentivoglio (Italy), F.C. Boyer (France),
A. Brashear (USA), A. Csanyi (Hungary), T. Deltombe
(Belgium), Z. Denes (Hungary), S. Edgley (USA), F. Gul
(USA), J.-M. Gracies (France), P. Hedera (USA),
S. Isaacson (USA), M.-E. Isner-Horobeti (France), R. Jech
1189C. Marciniak et al. / PM R 9 (2017) 1181-1190(Czech Republic), A. Kaminska (Poland), S. Khatkova
(Russia), S. Kocer (France), T. Lejeune (Belgium),
P. McAllister (USA), C. Marciniak (USA), P. Marque
(France), M. O’Dell (USA), O. Remy-Neris (France),
B. Rubin (USA), M. Rudzinska-Bar (Poland), D. Simpson
(USA), A. Skoromets (Russia), S.L. Timerbaeva (Russia),
P. Valkovic (Slovakia), M. Vecchio (Italy), H. Walker
(USA), M. Wimmer (USA).Supplementary Data
Supplementary data associated with this article can
be found in the online version at http://dx.doi.org/
10.1016/j.pmrj.2017.06.007.
References
1. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of
botulinum toxin type A on disability and carer burden due to arm
spasticity after stroke: A randomised double blind placebo
controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-221.
2. Foley N, Pereira S, Salter K, et al. Treatment with botulinum toxin
improves upper-extremity function post stroke: A systematic re-
view and meta-analysis. Arch Phys Med Rehabil 2013;94:977-989.
3. Gracies JM. Pathophysiology of spastic paresis. I: Paresis and soft
tissue changes. Muscle Nerve 2005;31:535-551.
4. Gracies JM. Pathophysiology of spastic paresis. II: Emergence of
muscle overactivity. Muscle Nerve 2005;31:552-571.
5. McCrory P, Turner-Stokes L, Baguley IJ, et al. Botulinum toxin A for
treatment of upper limb spasticity following stroke: A multi-centre
randomized placebo-controlled study of the effects on quality of life
and other person-centred outcomes. J Rehabil Med 2009;41:536-544.
6. Royal College of Physicians, British Society of Rehabilitation Med-
icine, Chartered Society of Physiotherapy, Association of Char-
tered Physiotherapists Interested in Neurology. Spasticity in
adults: Management using botulinum toxin. National guidelines.
2009. Available at https://www.kcl.ac.uk/lsm/research/divisions/
cicelysaunders/attachments/Spasticity-in-adults--management-using-
botulinum-toxin-National-guidelines.pdf. Assessed July 6, 2017.
7. Simpson DM, Gracies JM, Graham HK, et al. Assessment: Botulinum
neurotoxin for the treatment of spasticity (an evidence-based
review): Report of the Therapeutics and Technology Assessment
Subcommittee of the American Academy of Neurology. Neurology
2008;70:1691-1698.
8. Suputtitada A, Suwanwela NC. The lowest effective dose of bot-
ulinum A toxin in adult patients with upper limb spasticity. Disabil
Rehabil 2005;27:176-184.
9. Esquenazi A, Albanese A, Chancellor MB, et al. Evidence-based
review and assessment of botulinum neurotoxin for the treatmentof adult spasticity in the upper motor neuron syndrome. Toxicon
2013;67:115-128.
10. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on
the use of botulinum toxin type A in adult spasticity. J Rehabil Med
2009;41:13-25.
11. Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ.
Cerebral palsy I. Botulinum toxin assessment, intervention
and after-care for upper limb hypertonicity in adults: Inter-
national consensus statement. Eur J Neurol 2010;17(Suppl 2):
74-93.
12. Electronic Medicines Compendium. Dysport 300 units. Summary
of Product Characteristics. 2016. Available at https://www.
medicines.org.uk/emc/medicine/870/SPC/Dysportþ300þunits,þ
Dysportþ500þunits/. Assessed July 6, 2017.
13. Ipsen Biopharm Ltd. Dysport Full Perscribing Information. 2016.
Available at https://www.dysport.com/pdfs/Dysport_Full_
Prescribing_Information.pdf. Assessed July 6, 2017.
14. Gracies JM, Brashear A, Jech R, et al. Safety and efficacy of
abobotulinumtoxinA for hemiparesis in adults with upper limb
spasticity after stroke or traumatic brain injury: A double-
blind randomised controlled trial. Lancet Neurol 2015;14:
992-1001.
15. Bohannon RW, Smith MB. Interrater reliability of a Modified Ash-
worth Scale of muscle spasticity. Phys Ther 1987;67:206-207.
16. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of
botulinum toxin for the treatment of wrist and finger spasticity
after a stroke. N Engl J Med 2002;347:395-400.
17. Brashear A, Zafonte R, Corcoran M, et al. Inter- and intrarater
reliability of the Ashworth Scale and the Disability Assessment
Scale in patients with upper-limb poststroke spasticity. Arch Phys
Med Rehabil 2002;83:1349-1354.
18. Gracies JM, Bayle N, Vinti M, et al. Five-step clinical assess-
ment in spastic paresis. Eur J Phys Rehabil Med 2010;46:
411-421.
19. Gracies JM, Burke K, Clegg NJ, et al. Reliability of the Tardieu
Scale for assessing spasticity in children with cerebral palsy. Arch
Phys Med Rehabil 2010;91:421-428.
20. Picelli A, Lobba D, Midiri A, et al. Botulinum toxin injection into
the forearm muscles for wrist and fingers spastic overactivity
in adults with chronic stroke: A randomized controlled trial
comparing three injection techniques. Clin Rehabil 2014;28:
232-242.
21. Dashtipour K, Chen JJ, Walker HW, Lee MY. Systematic literature
review of abobotulinumtoxinA in clinical trials for adult upper limb
spasticity. Am J Phys Med Rehabil 2015;94:229-238.This journal-based CME activity is designated for 1.0 AMA PRA
Category 1 Credit and can be completed online at www.me.
aapmr.org. This activity is FREE to AAPM&R members and avail-
able to nonmembers for a nominal fee. For assistance with claim-
ing CME for this activity, please contact (847) 737-6000.DisclosureC.M. Shirley Ryan AbilityLab, 355 East Erie St, Chicago, IL 60611; Department of
Physical Medicine and Rehabilitation and Department of Neurology, North-
western University Feinberg Medical School, Chicago, IL. Address correspon-
dence to: C.M.; e-mail: cmarciniak@sralab.org
Disclosures related to this publication: Ipsen (institution received research
funding for this research project)
Disclosures outside this publication: Allergan (institution received research
funding), Merz (institution received research funding, and the institution was
also paid for C.M.’s work on an advisory board), Ipsen (instituion receivedresearch funding for a research project apart from that reported in this
manuscript)
P.M. New England Institute for Neurology and Headache, Stamford, CT
Disclosures outside this publication: personal fees, Ipsen (speaker’s bureau)
H.W. Frank Porter Graham Child Development Institute, University of North
Carolina, Chapel Hill, NC
Disclosures outside this publication: speaker panel, Ipsen, Merz
1190 AbobotulinumtoxinA for Hemiparesis in Upper Limb SpasticityA.B. Department of Neurology, Wake Forest University Baptist Medical Center,
Winston-Salem, NC
Disclosures related to this publication: consultant, Ipsen, Worldmeds, Revance;
salary support, NINDS
Disclosures outside this publication: consultant, Ipsen, Worldmeds, Revance;
salary support, NINDS
S.E. Division of Physical Medicine and Rehabilitation, University of Utah School
of Medicine, Salt Lake City, UT
Disclosures related to this publication: grant, University of Utah Division of PM&R
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